RBM3 and pancreatic adenocarcinoma: In support of this notion, RBM3 expression status has in several studies been recognized as a predictor of chemoresponsiveness, including gemcitabine and 5-fluorouracil (5-FU) in pancreatic adenocarcinoma [18], oxaliplatin-based chemotherapy in metastatic colorectal cancer [11] as well as of the effect of cisplatin in metastatic testicular non-seminomatous germ cell cancer [39] and epithelial ovarian cancer [16].